Transglutaminase Activity as a Possible Therapeutical Target in Neurodegenerative Diseases

ISSN: 2212-3954 (Online)
ISSN: 1574-8898 (Print)

Volume 10, 2 Issues, 2015

Download PDF Flyer

Recent Patents on CNS Drug Discovery

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Vincenzo Di Marzo
Istituto di Chimica Biomolecolare (I.C.B.)
Consiglio Nazionale delle Ricerche (C.N.R.)
Via Campi Flegrei 34
Pozzuoli, Napoli 80078

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Transglutaminase Activity as a Possible Therapeutical Target in Neurodegenerative Diseases

Recent Patents on CNS Drug Discovery, 8(3): 235-242.

Author(s): Martina Iannaccone, Federica Titta, Enrica Serretiello, Giulia De Vivo, Antonio Martin and Vittorio Gentile.

Affiliation: Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, via Costantinopoli 16, 80138 Naples, Italy.


Transglutaminases are ubiquitous enzymes which catalyze post-translational modifications of proteins. The main activity of these enzymes is the cross-linking of glutaminyl residues of a protein/peptide substrate to lysyl residues of a protein/peptide co-substrate. In addition to lysyl residues, other second nucleophilic co-substrates may include monoamines or polyamines (to form mono- or bi-substituted /crosslinked adducts) or –OH groups (to form ester linkages). In absence of co-substrates, the nucleophile may be water, resulting in the net deamidation of the glutaminyl residue. Transglutaminase activity has been suggested to be involved in molecular mechanisms responsible for both physiological or pathological processes. For example, neurodegenerative diseases, such as Alzheimer’s Disease, Parkinson’s Disease, supranuclear palsy, Huntington’s Disease and other polyglutamine diseases, are characterized in part by aberrant cerebral transglutaminase activity and by increased cross-linked proteins in affected brains. This review focuses on the possible molecular mechanisms responsible for such diseases and on the possible therapeutic effects of selective transglutaminase inhibitors for patients with diseases characterized by aberrant transglutaminase activity. The article presents some promising patents on the transglutaminase activity.


Cystamine, neurodegenerative diseases, post-translational modifications of proteins, protein aggregation, transglutaminases, transglutaminase inhibitors.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 8
Issue Number: 3
First Page: 235
Last Page: 242
Page Count: 8
DOI: 10.2174/1574889808666131128105630

Related Journals

Webmaster Contact: Copyright © 2015 Bentham Science